Analysts Set Intuitive Surgical, Inc. (NASDAQ:ISRG) Target Price at $396.17

Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) have received an average recommendation of “Moderate Buy” from the seventeen brokerages that are presently covering the stock, MarketBeat reports. Four investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $396.17.

Several research firms have issued reports on ISRG. BTIG Research boosted their price objective on shares of Intuitive Surgical from $412.00 to $421.00 and gave the company a “buy” rating in a research report on Friday, April 19th. StockNews.com lowered shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a report on Thursday, February 29th. Robert W. Baird reduced their price target on shares of Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a report on Friday, April 19th. Piper Sandler boosted their price target on shares of Intuitive Surgical from $425.00 to $435.00 and gave the company an “overweight” rating in a report on Friday, April 19th. Finally, Jefferies Financial Group boosted their price target on shares of Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a report on Friday, April 19th.

Insider Buying and Selling

In related news, Director Alan J. Levy sold 2,000 shares of the stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total transaction of $741,400.00. Following the sale, the director now directly owns 25,319 shares of the company’s stock, valued at $9,385,753.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Intuitive Surgical news, SVP Mark Brosius sold 175 shares of the company’s stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $387.22, for a total transaction of $67,763.50. Following the completion of the transaction, the senior vice president now directly owns 533 shares in the company, valued at $206,388.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Alan J. Levy sold 2,000 shares of the company’s stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total transaction of $741,400.00. Following the transaction, the director now owns 25,319 shares of the company’s stock, valued at $9,385,753.30. The disclosure for this sale can be found here. Over the last three months, insiders have sold 148,290 shares of company stock valued at $57,207,154. Corporate insiders own 0.90% of the company’s stock.

Institutional Investors Weigh In On Intuitive Surgical

Hedge funds have recently modified their holdings of the business. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA increased its position in Intuitive Surgical by 0.3% during the fourth quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 8,899 shares of the medical equipment provider’s stock worth $3,002,000 after purchasing an additional 27 shares during the last quarter. Advance Capital Management Inc. increased its position in Intuitive Surgical by 3.8% during the first quarter. Advance Capital Management Inc. now owns 740 shares of the medical equipment provider’s stock worth $295,000 after purchasing an additional 27 shares during the last quarter. Perigon Wealth Management LLC increased its position in Intuitive Surgical by 0.5% during the first quarter. Perigon Wealth Management LLC now owns 5,363 shares of the medical equipment provider’s stock worth $2,140,000 after purchasing an additional 27 shares during the last quarter. Sugarloaf Wealth Management LLC increased its position in Intuitive Surgical by 5.7% during the first quarter. Sugarloaf Wealth Management LLC now owns 534 shares of the medical equipment provider’s stock worth $213,000 after purchasing an additional 29 shares during the last quarter. Finally, Sheaff Brock Investment Advisors LLC increased its position in Intuitive Surgical by 1.3% during the fourth quarter. Sheaff Brock Investment Advisors LLC now owns 2,226 shares of the medical equipment provider’s stock worth $751,000 after purchasing an additional 29 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Trading Up 1.6 %

ISRG stock opened at $404.85 on Wednesday. Intuitive Surgical has a 12 month low of $254.85 and a 12 month high of $408.43. The company has a 50-day moving average price of $386.45 and a 200 day moving average price of $362.07. The stock has a market cap of $143.60 billion, a PE ratio of 73.08, a P/E/G ratio of 5.18 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The firm had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. During the same period in the previous year, the company earned $1.00 EPS. The firm’s revenue for the quarter was up 11.5% compared to the same quarter last year. Sell-side analysts forecast that Intuitive Surgical will post 4.8 EPS for the current year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.